245 First Street - 18th Floor
Fax: 617- 444-8405
About GENFIT CORP.Genfit is a biopharmaceutical company, listed on Alternext by Euronext™ Paris (ALGFT - FR0004163111) with headquarters in Lille, France and a US subsidiary in Cambridge, Massachusetts.
Through its world-renowned scientific expertise, particularly in the field of nuclear receptors, Genfit’s research efforts are focused on the discovery and development of new treatments mainly in the growing therapeutic areas of Cardiometabolic and Neurodegenerative disorders, such as prediabetes/diabetes, atherosclerosis, dyslipidemia, obesity, and Alzheimer’s. Genfit uses a multi-pronged approach based on early diagnosis, preventive solutions, and therapeutic treatments to address these major public health problems and their unmet medical needs.
Genfit has an original business model built on both proprietary internal programs and a strong track record of partner-supported programs and collaborations. This strategy allows the company to efficiently manage the risks associated with the internal programs, and at the same time build value for its shareholders. Genfit, on its own or in collaboration with its major pharmaceutical partners, has thus created a rich and diversified pipeline of drug candidates in pre-clinical and clinical development, as well as a broad intellectual property portfolio.
Genfit’s strong portfolio of therapeutic products, tools, and clinical biomarkers, together with its scientific expertise, have made the Company into a European biotechnology leader.
Parc Eurasanté – Lille Metropole
885 Avenue Eugene Avinee
Tel : +33 (0)3 2016 4000
Fax : +33 (0)3 2016 4001
184 articles with GENFIT CORP.
Cash and cash equivalents of €219.9 million at September 30, 2018
GENFIT: New data to be presented at 2018 AASLD meeting, ahead of key results expected in 2018 and 2019
KOL event to be held ahead of expected data release with elafibranor in PBC by end of 2018 (Phase 2) and in NASH end of 2019 (Phase 3)
Is NASH Really a $35 Billion Opportunity? And could it be the middle of the pack that wins the prize? For the last few years, investors have been talking up the huge potential of drugs to treat nonalcoholic steatohepatitis, also known as NASH.
GENFIT today provides further details on the management changes announced in its September 24, 2018 press release.
GENFIT today announces some key leadership changes to accompany GENFIT into the next stage of its development and its evolution from an R&D biotechnology company to a fully-integrated biopharmaceutical company.
2018 HALF-YEAR RESULTS: CASH POSITION AT END OF PERIOD AT €238M AND SIGNIFICANT ADVANCES IN THE CLINICAL DEVELOPMENT OF ELAFIBRANOR
Completion of enrollment of approx. 1000-patient study cohort for Phase 3 RESOLVE-IT study, on the basis of which conditional marketing approval for elafibranor in NASH could be obtained in 2020. Interim data readout expected by end of 2019.
San Diego-based Viking Therapeutics announced positive top-line data from a 12-week Phase II clinical trial of VK2809 in non-alcoholic fatty liver disease (NAFLD) and elevated low-density lipoprotein cholesterol (LDL-C).
GENFIT announces its upcoming participation in a number of investor and NASH-specific events over the next two months
GENFIT today announces its participation in numerous investor healthcare conferences both in Europe and the United States.
GENFIT: Major Milestone achieved with full recruitment of the Phase 2 trial evaluating elafibranor in PBC
GENFIT (Euronext: GNFT - ISIN: FR0004163111), is a biopharmaceutical company focused on discovering and developing drug candidates and diagnostic solutions targeting liver diseases, in particular those of metabolic origin, and hepatobiliary diseases today announces the completion of enrolment in the Phase 2a trial evaluating elafibranor in PBC (Primary Biliary Cholangitis), a rare liver disease.
GENFIT: Official Launch of the NASH Pediatric Program, Following PIP and PSP Agreement by EMA and FDA
The PSP agreement by the FDA will lead to the launch of the first pediatric trial to evaluate the safety and efficacy of elafibranor in children with NASH.
Under the liquidity contract granted to CIC by GENFIT, the following resources were in the liquidity account as at Decembrer 31, 2017:
The financial calendar for 2018 is set as follows.
LITMUS (The Liver Investigation: Testing Marker Utility in Steatohepatitis) is a European consortium that brings together clinicians and scientists from prominent academic centers across Europe.
GENFIT: Positive Outcome From the 18-month Pre-Planned Safety Review by the DSMB, in RESOLVE-IT Phase III Clinical Trial With elafibranor
NASH being considered as a chronic condition, safety is crucial for any drug candidate aiming to address the unmet clinical needs related to this pathology.
Genfit Completes a 180M Euro Offering of Bonds Convertible Into New Shares and/or Exchangeable for Existing Shares ("Oceanes") Due 2022
Following strong demand from investors - the Offering was multiple times overscribed - the initial amount of the Offering was increased from 150 to 180 million euros.
GENFIT Launches An Offering Of Bonds Convertible Into New Shares And/Or Exchangeable For Existing Shares ("Oceanes") Due 2022 For An Amount Of Approximately Eur150 Million
GENFIT: 2017 Half-Year Results: Cash Position At End Of Period At €126M And Significant Advances In The Company's Pipeline
GENFIT: Risk Of Confusion Between PPAR Alpha/Delta Phase III Drug Candidate Elafibranor And PPAR A/D/Gamma Phase II Compound Lanifibranor